health canada approval zepbound tirzepatide obesity canada 2024 2025 🇨🇦 has approved for the treatment of obstructive sleep apnea in adults living with obesity, making it the first and only GLP-1 medication in approved for the sleep Zepbound approved in Canada for

Patients may request telehealth consultations in Florida or ask whether peptide therapy may be appropriate based on their goals and health history

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society

607 A randomized, double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological, and clinical measures in patients with T2DM with symptomatic polyneuropathy is undergoing

Active individuals may also explore injury recovery peptides to support the increased training volume that tirzepatide-enhanced body composition enables, and energy-boosting strategies to maintain training intensity during caloric restriction

Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study

Research suggests that GLP-1s may affect immune cells and lower levels of inflammatory cytokines, such as TNF and IL-6, which are also involved in RA